Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

Overview of attention for article published in ClinicoEconomics and Outcomes Research: CEOR, May 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

policy: 3 policy sources
twitter: 7 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 26 Dimensions

Readers on

mendeley: 64 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Dimensions has found 26 publications that cite this research output.

26

The most recent citing publications are shown below. View all 26 publications that cite this research output on Dimensions.

Anti-VEGF Drugs Compared with Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A Cost-Effectiveness Analysis

Article in Value in Health (March 2024)

Healthcare expenditure of intravitreal anti‐vascular endothelial growth factor inhibitors compared with dexamethasone implant for diabetic macular oedema

Article in Acta Ophthalmologica (April 2022)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis

Article in Journal of Managed Care & Specialty Pharmacy (June 2021)